With a pool of talented scientists from world-class institutes across the globe and state of the art facilities, R&D is focused on developing high quality recombinant therapeutic proteins to address the unmet medical needs across the globe. The current focus is on development and commercialization of products in Oncology (Cancer), Auto-Immune Disease, Ophthalmology and Nephrology.
Fully integrated R&D team has end-to-end expertise for biosimilar product development; ranging from clone development to the clinical research. Dedicated group for Analytical development and biocharachterization to support CQA and QbD based product development. A dedicated Quality Assurance team works closely with R&D to ensure highest standards for documentation and regulatory submissions.